Menu
ETF
Annual · values202520242023202220212020201920182017201620152014
Gross Margin61.87%61.59%59.03%47.43%55.20%57.39%58.87%56.32%60.17%55.78%54.53%68.59%
Operating Margin6.10%0.04%-11.19%-43.46%-41.67%-49.94%-30.53%-53.03%-58.44%-123.66%-175.98%-152.69%
EBITDA Margin6.84%1.00%-9.69%-41.27%-39.73%-47.69%-28.73%-50.17%-52.72%-122.84%-175.93%-152.35%
Net Margin6.35%0.52%-11.06%-71.24%-37.17%-52.87%-33.09%-59.82%-21.24%-130.69%-158.85%-421.68%
Current Ratio4.065.313.985.855.7011.443.423.082.041.412.571.35
Quick Ratio2.893.642.813.623.707.432.362.381.680.881.951.20
Debt / Equity0.010.020.040.110.15
ROE11.70%0.86%-18.84%-80.01%-26.22%-29.06%-44.48%-50.04%-41.49%-454.57%-115.92%129.75%
ROA8.75%0.66%-13.28%-64.61%-21.91%-24.45%-29.41%-32.22%-16.24%-113.22%-77.78%-218.79%
Asset Turnover1.381.261.200.910.590.460.890.540.760.870.490.52
Book Value / Share0.930.810.800.861.471.721.020.110.040.010.08-0.24

Nephros Inc. is a company that specializes in the development and sale of filtration and ultrafiltration devices. Primarily focusing on providing high-quality, robust filtration solutions, Nephros serves medical institutions, commercial facilities, and the military sector. The company's product portfolio includes hemodiafilters and ultrafilters, which are integral in kidney dialysis and ensuring water is adequately purified for various healthcare and industrial applications. Nephros's technological advancements in filtration enhance safety and operational efficiency, impacting sectors like healthcare equipment manufacturing, water treatment, and hospitality services. By addressing the critical need for clean water and advanced dialysis treatments, Nephros plays a vital role in both enhancing public health standards and improving patient outcomes in medical settings.